ContraFect Corporation Profile Avatar - Palmy Investing

ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes …

Biotechnology
US, Yonkers [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
ContraFect Corporation can't present any analysts estimates at the moment detail analysis.
End of CFRX's Analysis
CIK: 1478069 CUSIP: 212326300 ISIN: US2123264093 LEI: - UEI: -
Secondary Listings
CFRX has no secondary listings inside our databases.